dnf忍者

ABOUT US

History
HOME > ABOUT US > History
  • 2018

    Shandong Saikesaisi Biotechnology Co., Ltd. was recognized as a national high-tech enterprise by the Ministry of Science and Technology
    Shandong Saikesaisi Biotechnology Co., Ltd. Approved to Establish Postdoctoral Innovation Practice Workstation
    The SaiNaoning? absorbable dura mater seal medical approval certificate was approved. It is a green channel product specially approved by the CFDA for approval of China's first innovative medical device.
    Saikesaisi medical device new production plant area (Sun Village) main body cap

  • 2017

    Shandong Saikesaisi Biotech Co., Ltd. Sales Branch expanded to 23 companies

    Shandong Saikesaisi Biotechnology Co., Ltd. convenes the first shareholders meeting to elect directors and supervisors

  • 2016

    Construction of the Saikesaisi Medical Devices New Manufacturing Plant (Sun Village) Foundation Project kicked off

  • 2015

    Shandong Saikesaisi Biotechnology Co., Ltd. increased its sales branch to 20, covering Shanxi, Shaanxi, Zhejiang, Jilin, Jiangxi, Fujian, Inner Mongolia and Sichuan.

  • 2014

    Shandong Saikesaisi Bio-Technology Co., Ltd. Sales Subsidiary was established in Anhui, Jiangsu, Hunan, Shanghai, Guangdong, Shandong, Qingdao, Hebei, Hubei

    Qilu Hemodialysis Service Management Co., Ltd. was established as a standardized chain operating agency providing integrated medical services for patients with end-stage renal disease.

  • 2013

    Shandong Yikeyuan Stem Cell Bioengineering Co., Ltd. was established

  • 2012

    Shandong Saikesaisi Biotech Co., Ltd.'s first sales subsidiary was established in Henan Province

    Instantaneous Absorbable Polysaccharide Hemostatic Material approved by CFDA is the only haemostatic material combining plant starch and carboxymethyl chitosan in the world. It is suitable for hemostasis in the hemorrhage area of various surgical tissue wounds such as cardiothoracic surgery and neurosurgery.

    EVAL? non-adhesive liquid embolic agent approved CFDA is the world's second non-adhesive embolic agent listed in the world after ONYX products in the United States, and is the only domestic brand to date.

  • 2011

    Acquired the establishment of the Shandong Province's pluripotent stem cell bank with the approval of the Department of Health, and established professional institutions for R&D and storage based on placenta-derived stem cell products.

    Duo Ying Investment Management Co., Ltd. was established. This is a professional investment company with core business of venture capital investment and equity investment management business.

  • 2008

    2008 The first self-developed product, Septim? surgical anti-blocking liquid was approved by CFDA

  • 2007

    The Jinan Institute of Applied Chemicals acquired and merged into Saikesaisi Holding Group and changed its name to Shandong Saikesaisi Hydrogen Energy Co., Ltd., and the Group's development field gradually expanded to the new energy industry.

  • 2005

    Saikesaisi Holding Group reorganized and restructured the former Jinan Aluminum Products Factory and Jinan Carpet General Factory and established Shandong Saikesaisi New Materials Co., Ltd.

  • 2003

    Shandong Saikesaisi Bio-Technology Co., Ltd. was established and turned to the medical device industry to create a manufacturing enterprise integrating R&D, production, sales and service.

  • 2001

    Hainan Fengning Co., Ltd. was renamed as Hainan Saikesaisi Pharmaceutical Co., Ltd., and now Shandong Saikesaisi Pharmaceutical Sales Co., Ltd. as the main body to carry out new special drug sales, drug promotion and other services.

  • 1999

    Acquired Hainan Xinte Pharmaceutical Co., Ltd. and founded Hainan Fengning Co., Ltd., mainly engaged in drug sales services

  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2008
  • 2007
  • 2005
  • 2003
  • 2001
  • 1999
dnf忍者 燕赵福彩排列七今晚开奖结果 安徽时时走势图官方网站 北京现场赛车开奖网站 山东时时 福彩3d黑彩倍率 澳门时时彩正规平台 捕鱼机遥控器 全民欢乐捕鱼 那里能投山西11选5 二维码软件公司